Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY

Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 3,071.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,268,532 shares of the company’s stock after acquiring an additional 1,228,532 shares during the period. Bamco Inc. NY owned about 1.28% of ARS Pharmaceuticals worth $12,749,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Rubric Capital Management LP raised its position in ARS Pharmaceuticals by 247.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,500,000 shares of the company’s stock valued at $45,225,000 after purchasing an additional 3,205,122 shares in the last quarter. Vanguard Group Inc. grew its position in shares of ARS Pharmaceuticals by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after buying an additional 237,630 shares in the last quarter. Aberdeen Group plc increased its stake in shares of ARS Pharmaceuticals by 106.1% during the third quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock valued at $31,125,000 after buying an additional 1,594,447 shares during the period. Franklin Resources Inc. increased its stake in shares of ARS Pharmaceuticals by 31.1% during the third quarter. Franklin Resources Inc. now owns 2,398,012 shares of the company’s stock valued at $24,100,000 after buying an additional 569,257 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of ARS Pharmaceuticals in the second quarter valued at about $30,154,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Price Performance

SPRY opened at $8.39 on Monday. The firm has a market capitalization of $833.13 million, a PE ratio of -4.79 and a beta of 0.78. The company has a debt-to-equity ratio of 1.47, a current ratio of 7.28 and a quick ratio of 7.06. The business’s 50-day moving average is $9.89 and its two-hundred day moving average is $9.92. ARS Pharmaceuticals, Inc. has a 1 year low of $6.66 and a 1 year high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.42) EPS for the quarter, meeting the consensus estimate of ($0.42). The business had revenue of $28.09 million during the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. Research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SPRY has been the subject of several recent research reports. Leerink Partners set a $26.00 price target on shares of ARS Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, March 10th. Zacks Research upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $29.33.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.